Data from clinical trials are subject to differing interpretations.

Additional risks and uncertainties that could results to differ materially results to differ materially from those expressed or implied by forward – looking statements include, third-party payments, the inherent uncertainty of of the timing and success of, and costs associated with research, development, regulatory approval and commercialization of our products and pipeline products, cost reduction measures, the authorities initiatives; restrictions third-party payments for our products; substantial competition in our industry, also branded and generic products, emerging data on our products and pipeline products, the importance of strong performance of our principal products and our anticipated new product introductions; highly regulated nature of our business, product liability, intellectual property and other litigation risks and environmental risks, uncertainty regarding our intellectual property rights and those of others, difficulties associated with, and regulatory compliance with respect to, manufacturing of our products, risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations, changes in Generally Accepted Accounting Principles, trade buying patterns, Ofof legislation and regulatory compliance, risks and uncertainties associated with global operations and sales, and other risks and uncertainties, including those detailed filed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8 – K, quarterly reports on Form 10-Q and annual report on Form 10 – K, particularly the discussion under the caption Item 1A, Risk Factors in our Annual Report on Form 10 – K for the year ended 31 December 2007, the 29 with the Securities and Exchange Commission February was filed, the forward-looking statements in this news release are qualified by these risk factors.

Director of the Maxine Dunitz Neurosurgical Institute and the Johnnie L. Cochran Jr. Brain Tumor Center, ‘Our aim is to revolutionize the way neurological disorders are treated. Are active and is an intra-operative of the several technologies that we are pursuing.

Leading scientists Ray Chu, a neurosurgeon and his co-principal investigator Babak Kateb, research assistant at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and chairman of the board of the Society for Brain Mapping and Therapeutics, said: ‘can ultraviolet imaging technique a’metabolic map ‘ of tumors that we distinguish between normal surrounding brain tissue, which real-time useful, intraoperative information could.‘.. Among the U.S. Congenital heart patients who have in need of treatment annually to pulmonic dysfunctional are about 1,500 candidate for aortic valve replacement with the Melody instrument. John Liddicoat disc, general manager of Cardio Vascular Structural Heart Disease business at Medtronic, open heart surgery success of the Melody valve stems directly from the cooperative approach Medtronic with physicians and scientists, technological has assumed development of The successful approach to be develop built the foundations a much wider a much larger program transcatheter valves all valve settings.

Promoting view of safety been a high acute procedural success rate of 98 %. To follow to every six months, has been maintained great valve skills was proven as the a corresponding, clinically significant reduction in excess of 18 % in the the right ventricular volumes. Valves of competence was rated by median pulmonary insufficiency fraction, which was as 0 %age from an initial value of 30 %.

Over MedtronicMedtronic, has its head office in Minneapolis, is the world leader in medical technology – alleviating pain, restoring health, and extending life for millions around the world.. Announces First U.S. Clinical Trials Data on Transcatheter Valve of for Congenital Heart Defects.

For on 66 patients registered on centers in Boston, Seattle, New York, Columbus and Miami.